Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis

Company Overview

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system. Hansa Biopharma also has research and development programs evaluating imlifidase and related technologies in additional transplant and autoimmune applications.

Hansa Biopharma is headquartered in Lund, Sweden, and serves specialist healthcare markets primarily in Europe, while pursuing opportunities in other international markets. The company was formerly known as Hansa Medical and adopted the Hansa Biopharma name in 2018. Its operations combine commercial activities for Idefirix with continued clinical development of treatments for rare diseases and conditions involving the immune system.

Key Stats

• Today's Range: $3.70 to $3.70
• 50-Day Range: $2.90 to $3.70
• 52-Week Range: $2.90 to $3.70
• Volume: N/A
• Average Volume: 10,133 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Hansa Biopharma AB (publ) Stock Analysis - MarketRank™

Hansa Biopharma AB (publ) scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Hansa Biopharma AB (publ) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hansa Biopharma AB (publ) has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hansa Biopharma AB (publ) is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hansa Biopharma AB (publ) is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Hansa Biopharma AB (publ) has a short interest ratio ("days to cover") of 51.46, which indicates bearish sentiment.

Change versus previous month

Short interest in Hansa Biopharma AB (publ) has recently decreased by 58.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hansa Biopharma AB (publ) does not currently pay a dividend.

Dividend Growth

Hansa Biopharma AB (publ) does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.18

News Sentiment

Hansa Biopharma AB (publ) has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Hansa Biopharma AB (publ) this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hansa Biopharma AB (publ) insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hansa Biopharma AB (publ) has minimal institutional ownership at this time.

Company Calendar

• Today: 9/28/2026
• Next Earnings (Estimated): 11/11/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HNSBF
• CIK: N/A
• Web: www.hansabiopharma.com
• Phone: 46 46 16 56 70
• Fax: N/A
• Employees: 146
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A